Halozyme Therapeutics press release (NASDAQ:HALO): Q2 Non-GAAP EPS of $0.53. Revenue of $152.37M. Financial Outlook for 2022 The Company is raising its financial guidance for 2022 which was last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback